12:00 AM
 | 
Mar 04, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

EB-1020: Phase I started

Neurovance began a crossover, Australian Phase I trial to compare multiple ascending-doses of oral sustained-release EB-1020 vs. immediate-release EB-1020 in about...

Read the full 85 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >